Sovereign wealth fund
Mubadala Capital portfolio
mubadalacapital.aeMubadala Capital is a sovereign wealth fund based in Al Maryah Island, United Arab Emirates, founded in 2011. It has invested in 61 venture-backed companies across 88 funding rounds on VCMC, and led 29 of those rounds. 10 of them were in the last 12 months.
61
Venture-backed companies
in its portfolio on VCMC
88
Funding rounds
led 29
10
Last 12 months
rounds, Oct 2025 to Sep 2026
18
With a disclosed valuation
of 61 companies
$100.1B
Combined value of its private companies
the whole companies, not what Mubadala Capital owns
59 private companies Mubadala Capital has backed have a VCMC valuation; together they are worth $100.1B. That is the value of the whole companies, not what Mubadala Capital owns. Crusoe is 32% of the total. 2 companies it backed have since been acquired and are not included. How VCMC values companies.
Values cover private companies only; public companies are not included.
Portfolio
Mubadala Capital's most valuable portfolio companies
The 10 most valuable private companies Mubadala Capital has backed, by VCMC's valuation. Values cover private companies only; public companies are not included.
- 1 Crusoe Hosting & Cloud Infrastructure Providers, Denver $31.7B range $26.9B – $46.2B Led at Series E, 2025
- 2 Binance Cryptocurrency, Singapore $22.3B range $11.9B – $34.0B Led at Growth, 2025
- 3 Tabby Payment Processing & Point of Sale $6.7B range $5.7B – $9.7B Led at Series A, 2020
- 4 Innovaccer Tech Companies, San Francisco $4.6B range $2.0B – $5.3B Led at Seed, 2015
- 5 BetterUp Professional & Management Training, Austin $3.8B range $392M – $6.7B Joined at Series D, 2021
- 6 Biotechnology $2.4B range $1.4B – $3.7B Led at Growth, 2025
- 7 Tech Companies, Austin $2.0B range $1.3B – $2.3B Joined at Series C, 2025
- 8 Ollin Biosciences Pharmaceutical Products, Austin $2.0B range $1.2B – $3.6B Led at Series A, 2025
- 9 Collective Health Insurance - Agents, Carriers & Brokers, San Francisco $1.8B range $277M – $2.2B Joined at Series E, 2019
- 10 Biotechnology, Seattle $1.6B range $340M – $2.5B Joined at Series A, 2021
Portfolio
Full Mubadala Capital portfolio (61 companies)
61 companies. Load more shows the rest.
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dott Bicycle Rental Services · led at Series B, 2019 | Series D Oct 2025 $17M | $283M | $145M – $433M | $282M (0%) | $34.3M | 3% | 643 | up | B | |
| 2 | Crusoe Hosting & Cloud Infrastructure Providers · led at Series E, 2025 | Series F Sep 2026 $3.90B | $31.7B | $26.9B – $46.2B | $40.2B (+27%) | $4.4B | 0% | 1,720 | growing | A | |
| 3 | Tabby Payment Processing & Point of Sale · led at Series A, 2020 | Series F Sep 2026 $233M | $6.7B | $5.7B – $9.7B | $8.4B (+26%) | $1.1B | 0% | 4,681 | growing | A | |
| 4 | Binance Cryptocurrency · led at Growth, 2025 | Growth Equity Jun 2025 $2.00B | $22.3B | $11.9B – $34.0B | $22.3B (0%) | $2.3B | 0% | 14,720 | up | B | |
| 5 | Flink Groceries Delivery · led at Series A, 2021 | Growth Equity Mar 2026 $100M | $1.2B | $782M – $1.4B | $1.2B (+2%) | $96.8M | 0% | 2,536 | flat | A | |
| 6 | Innovaccer Tech Companies · led at Seed, 2015 | Series F Jan 2025 $275M | $4.6B | $2.0B – $5.3B | $4.6B (0%) | $502M | 0% | 1,630 | flat | B | |
| 7 | Collective Health Insurance - Agents, Carriers & Brokers · since Series E, 2019 | Series F May 2021 $280M | $1.8B | $277M – $2.2B | $1.7B (-5%) | $244M | 0% | 791 | up | D | |
| 8 | BetterUp Professional & Management Training · since Series D, 2021 | Series E Oct 2021 $300M | $3.8B | $392M – $6.7B | $3.5B (-7%) | $765M | 15% | 2,704 | flat | D | |
| 9 | C2FO Loans & Financing · since Growth, 2022 | Growth Equity Apr 2025 $30M | $379M | $160M – $637M | $345M (-9%) | $33.0M | 46% | 589 | flat | C | |
| 10 | TIER Car Rental · led at Series C, 2020 | Series D Oct 2021 $200M | $226M | $133M – $700M | $225M (0%) | $252M | 97% | 415 | shrinking | C | |
| 11 | Ollin Biosciences Pharmaceutical Products · led at Series A, 2025 | Series B Jun 2026 $330M | $2.0B | $1.2B – $3.6B | $2.6B (+31%) | $283M | 0% | 28 | unknown | B | |
| 12 | Tech Companies · since Series B, 2018 | Series D Jun 2023 $69M | $330M | $119M – $1.6B | $216M (-35%) | $118M | 97% | 114 | down | D | |
| 13 | Tech Companies · led at Series D, 2021 | Series D Aug 2021 $100M | $143M | $84.0M – $447M | $128M (-11%) | $148M | 97% | 112 | shrinking | C | |
| 14 | Tech Companies · since Series A, 2021 | Series B Jul 2022 $75M | $687M | $61.9M – $1.1B | $672M (-2%) | $85.2M | 0% | 375 | up | D | |
| 15 | Tech Companies · since Series B, 2026 | Series B Sep 2026 $100M | $749M | $469M – $1.5B | $995M (+33%) | $118M | 17% | 98 | flat | B | |
| 16 | Tech Companies · since Series A, 2022 | Series A Feb 2022 $40M | $25.5M | $10.2M – $80.4M | $24.4M (-4%) | $35.8M | 97% | 56 | shrinking | D | |
| 17 | Insurance - Agents, Carriers & Brokers · led at Series B, 2025 | Series B Oct 2025 $22M | $296M | $140M – $420M | $296M (0%) | $32.6M | 0% | 101 | growing | B | |
| 18 | Insurance - Agents, Carriers & Brokers · led at Series B, 2020 | Series B Jan 2020 $27M | $58.7M | $11.2M – $189M | $57.9M (-1%) | $26.2M | 57% | 72 | flat | D | |
| 19 | Tech Companies · since Series A, 2021 | Series A Nov 2021 $13M | $44.4M | $4.78M – $195M | $43.5M (-2%) | $20.0M | 59% | 112 | flat | D | |
| 20 | Medical Supply Manufacturers · since Series B, 2023 | Series D Sep 2026 $250M | $1.0B | $869M – $1.5B | $1.3B (+28%) | $144M | 0% | 148 | growing | A | |
| 21 | Biotechnology · since Series C, 2022 | Series C Feb 2022 $150M | $126M | $60.5M – $561M | $119M (-5%) | $145M | 97% | 57 | shrinking | D | |
| 22 | Tech Companies · since Series C, 2025 | Series C Jul 2025 $150M | $2.0B | $1.3B – $2.3B | $2.0B (0%) | $219M | 0% | 593 | up | A | |
| 23 | Banks & ATMs · led at Series B, 2022 | Series B Jun 2022 $206M | $1.0B | $68.7M – $1.7B | $946M (-6%) | $156M | 0% | 313 | flat | D | |
| 24 | Tech Companies · led at Series A, 2020 | Series B Mar 2026 $33M | $216M | $139M – $333M | $192M (-11%) | $37.9M | 91% | 412 | down | B | |
| 25 | Pharmaceutical Products · led at Bridge, 2024 | Series C Apr 2026 $28M | $300M | $173M – $521M | $342M (+14%) | $37.7M | 0% | 182 | growing | B | |
| 26 | Biotechnology · led at Growth, 2025 | Growth Equity Jan 2025 $200M | $2.4B | $1.4B – $3.7B | $2.4B (0%) | $220M | 0% | 53 | growing | B | |
| 27 | Biotechnology · since Series A, 2021 | Series B Aug 2024 $144M | $1.6B | $340M – $2.5B | $1.1B (-32%) | $178M | 0% | 75 | flat | C | |
| 28 | Biotechnology · led at Series C, 2021 | Series E Apr 2026 $40M | $1.2B | $869M – $1.5B | $1.3B (+15%) | $146M | 0% | 156 | up | A | |
| 29 | Biotechnology · led at Series A, 2023 | Series B Jan 2026 $107M | $1.1B | $555M – $1.7B | $1.2B (+10%) | $130M | 0% | 50 | up | B | |
| 30 | Tech Companies · led at Series A, 2021 | Series C Jun 2024 $80M | $850M | $338M – $1.2B | $835M (-2%) | $102M | 0% | 322 | up | C | |
| 31 | Electronical Components Manufacturing · led at Series C, 2025 | Series C Aug 2025 $55M | $585M | $277M – $896M | $571M (-2%) | $72.0M | 8% | 135 | flat | B | |
| 32 | Biotechnology · since Series B, 2023 | Series B Mar 2023 $135M | $82.8M | $54.7M – $181M | $45.3M (-45%) | $50.9M | 97% | 13 | shrinking | B | |
| 33 | Biotechnology · since Seed, 2020 | Series B Oct 2025 $54M | $476M | $258M – $736M | $401M (-16%) | $67.1M | 59% | 81 | flat | B | |
| 34 | Software Development Services · since Series C, 2021 | Series C Sep 2021 $80M | $884M | $125M – $1.0B | $865M (-2%) | $105M | 1% | 1,041 | up | D | |
| 35 | Software Development Services · since Series B, 2023 | Growth Equity Jul 2024 $100M | $426M | $128M – $604M | $364M (-15%) | $46.8M | 0% | 1,252 | flat | C | |
| 36 | Software Development Services · since Series B, 2022 | Series C Feb 2024 $50M | $344M | $105M – $751M | $214M (-38%) | $59.6M | 59% | 74 | flat | C | |
| 37 | Cybersecurity · led at Series B, 2018 | Acquisition Nov 2025 | $174M acquired 2025 | $81.9M – $581M | – | – | 97% | 94 | shrinking | C | |
| 38 | Metal Fabrication Services · led at Series B, 2026 | Series B Jan 2026 | $950M | $353M – $2.1B | $1.1B (+11%) | $116M | 0% | 123 | growing | C | |
| 39 | Biotechnology · since Series A, 2022 | Series B Feb 2025 $27M | $132M | $74.2M – $279M | $82.4M (-37%) | $28.7M | 97% | 18 | shrinking | C | |
| 40 | Psychiatrists & Psychiatric Hospitals · led at Series A, 2026 | Series A Feb 2026 $80M | $678M | $308M – $1.3B | $845M (+25%) | $118M | 0% | 96 | growing | C | |
| 41 | Biotechnology · led at Series A, 2022 | Series B Jan 2026 $34M | $275M | $153M – $436M | $264M (-4%) | $38.3M | 48% | 42 | flat | B | |
| 42 | Biotechnology · since Series B, 2023 | Series B Sep 2023 $75M | $174M | $90.7M – $454M | $96.3M (-45%) | $88.4M | 97% | 7 | shrinking | C | |
| 43 | Biotechnology · since Series A, 2023 | Series A Aug 2023 $75M | $584M | $57.7M – $1.4B | $542M (-7%) | $127M | 0% | 29 | flat | D | |
| 44 | Biotechnology · since Growth, 2024 | Growth Equity Dec 2024 $75M | $555M | $325M – $1.1B | $332M (-40%) | $82.5M | 97% | 63 | shrinking | C | |
| 45 | Tech Companies · since Series D, 2021 | Growth Equity Jun 2022 $26M | $272M | $40.0M – $408M | $268M (-2%) | $27.9M | 0% | 177 | up | D | |
| 46 | Biotechnology · led at Series A, 2022 | Series A Sep 2022 $73M | $492M | $32.7M – $1.1B | $454M (-8%) | $111M | 5% | 50 | flat | D | |
| 47 | Tech Companies · led at Series B, 2021 | Series C Aug 2025 $7.5M | $73.1M | $40.2M – $116M | $61.1M (-16%) | $9.63M | 59% | 51 | flat | B | |
| 48 | Medical Research · since Growth, 2020 | Acquisition Jan 2024 $38M | $306M acquired 2024 | $79.4M – $761M | – | – | 52% | 460 | down | D | |
| 49 | Insurance - Agents, Carriers & Brokers · since Series A, 2021 | Series B Apr 2024 $60M | $548M | $185M – $1.0B | $470M (-14%) | $75.1M | 26% | 105 | up | C | |
| 50 | Pharmaceutical Products · since Series A, 2024 | Series A Sep 2024 $65M | $676M | $128M – $1.0B | $525M (-22%) | $94.6M | 0% | 43 | flat | D |
Valuation: VCMC's valuation with its range, from a low to a high scenario; a company with no valuation shows a dash, one acquired after its last round its last value as a private company.
Activity
How Mubadala Capital invests: stages, industries and countries
Most of its rounds are Series C and later (36%). Its companies span 25 industries, most in Biotechnology, Tech Companies and Insurance - Agents, Carriers & Brokers, across 13 countries.
Rounds by stage
- Seed 3
- Series A 25
- Series B 27
- Series C and later 32
- Other venture 1
Investments by industry
- Biotechnology 15
- Tech Companies 15
- Insurance - Agents, Carriers & Brokers 4
- Software Development Services 4
- Pharmaceutical Products 3
- Banks & ATMs 1
- Bicycle Rental Services 1
- Car Rental 1
Investments by country
- United States 42
- United Kingdom 4
- France 2
- Germany 2
- Sweden 2
- United Arab Emirates 2
Recent rounds
Mubadala Capital's latest investments
Mubadala Capital's most recent funding rounds, newest first. 10 rounds in the last 12 months.
- Series D $250M 24 Sep 2026
- Crusoe Series F, led $3.90B 17 Sep 2026
- Series B $100M 2 Sep 2026
- Ollin Biosciences Series B $330M 24 Jun 2026
- Series E $40M 15 Apr 2026
- Series A, led $80M 26 Feb 2026
- Series B, led amount not disclosed 22 Jan 2026
- Series B $34M 12 Jan 2026
- Crusoe Series E, led $1.38B 24 Oct 2025
- Series B, led $22M 17 Oct 2025
Co-investors
Mubadala Capital's top co-investors
The investors that most often join the same rounds as Mubadala Capital. ARCH Venture Partners leads, with 8 rounds together.
- ARCH Venture Partners 8 rounds together
- DCVC 7 rounds together
- SoftBank Vision Fund 7 rounds together
- GV 7 rounds together
- B Capital 7 rounds together
- 7 rounds together
- 6 rounds together
- Founders Fund 6 rounds together
- M12 5 rounds together
- Tiger Global 5 rounds together
About
About Mubadala Capital
Mubadala Capital LLC is a global alternative asset management company engaged in private equity, special opportunities, venture capital, and private wealth management. The company serves institutional investors and focuses on markets such as Brazil and other international geographies. Mubadala Capital also operates as a sovereign wealth-affiliated alternative asset manager, providing investment strategies and access to high-potential opportunities through its global network and sovereign relationships.
Description from Veridion's company data.
- Founded
- 2011
- Based in
- Al Maryah Island, United Arab Emirates
- Team
- 230 people
- Type
- Sovereign wealth fund
Focus markets
- Financial Services
- Real Estate
- Insurance
- Wealth Management
What Mubadala Capital offers
- Alternative Asset Management Services
- Private Equity Investment Management
- Venture Capital Investment Management
- Special Opportunities Investment Management
- Private Wealth Management Services
- Institutional Investment Access Solutions
- Proprietary Investment Opportunity Sourcing
- Investment Underwriting and Risk Management
Questions
Mubadala Capital: frequently asked questions
How many companies has Mubadala Capital invested in?
61 venture-backed companies on VCMC, across 88 funding rounds.
What are Mubadala Capital's most valuable private companies?
Crusoe ($31.7B), Binance ($22.3B), Tabby ($6.7B), by VCMC's valuation.
What was Mubadala Capital's latest investment?
Precision Neuroscience, a Series D round in Sep 2026 of $250M.
Which stages does Mubadala Capital invest in?
Mubadala Capital invests most often at Series C and later (32 rounds), followed by Series B (27) and Series A (25). It has also joined 3 seed and 1 other venture rounds.
What is Mubadala Capital's portfolio worth?
Its private companies with a VCMC valuation are worth $100.1B together. That is the sum of the companies' values, not what Mubadala Capital owns.
Who does Mubadala Capital invest alongside?
ARCH Venture Partners (8 rounds), DCVC (7 rounds), SoftBank Vision Fund (7 rounds).